Munich—Global law firm Dentons has advised the medical technology manufacturer Coldplasmatech GmbH on an equity financing and associated strategic investment by the US company Royal Biologics.

Coldplasmatech emerged as a spin-off from the Leibniz Institute for Plasma Research e.V. in Greifswald. The company developed the first active dressing for the treatment of chronic wounds using cold, physical plasma, which protects the wound from bacteria and enhances cellular regeneration. With the help of the strategic partnership with Royal Biologics, Coldplasmatech can now further develop its wound healing technologies and open up new markets.

Royal Biologics is a leading orthobiologics and life science company in New Jersey, USA. The company is dedicated to advancing innovative healing solutions and offers various products for the orthobiologics and wound care industries.

Carsten Mahrenholz, CEO and founder of Coldplasmatech: “The partnership between Coldplasmatech and Royal Biologics is a decisive milestone for plasma medicine and offers the prospect of effective treatment for infected wounds that are slow to heal for patients worldwide.”

A team from Dentons, led by Munich-based partner Christopher Mayston, provided Coldplasmatech with comprehensive legal support throughout the transaction process.

Advisors to Coldplasmatech GmbH

Dentons (Munich):

Corporate/M&A: Christopher Mayston (Partner, Lead), Thomas Strassner (Partner), Dr. Michael Singer (Counsel), Edi Baqaie (Associate);

Commercial: Dr. Christiane Zedelius (Partner), Sarah Osipenco (Senior Associate);

Tax: Dr. Pia Dorfmueller (Partner), Konstantin Ecker (Associate)

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com